A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

ClinicalTrials.gov ID: NCT07007793

Public ClinicalTrials.gov record NCT07007793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone System (RAAS) in approximately 250 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and 12 countries.

Study identification

NCT ID: NCT07007793
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 250 participants

Conditions and interventions

Conditions

Primary Hyperaldosteronism

Interventions

Baxdrostat Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 6, 2025
Primary completion: Aug 12, 2027
Completion: Aug 13, 2028
Last update posted: Jul 5, 2026

2025 – 2028

United States locations

U.S. sites: 21
U.S. states: 15
U.S. cities: 20

Facility	City	State	ZIP	Site status
Research Site	Los Angeles	California	90048	Withdrawn
Research Site	San Francisco	California	94110	Active, not recruiting
Research Site	Farmington	Connecticut	06030	Active, not recruiting
Research Site	Chicago	Illinois	60611	Recruiting
Research Site	Springfield	Illinois	62702	Active, not recruiting
Research Site	Baltimore	Maryland	21287	Active, not recruiting
Research Site	Boston	Massachusetts	02111	Active, not recruiting
Research Site	Boston	Massachusetts	02115	Active, not recruiting
Research Site	Ann Arbor	Michigan	48109	Active, not recruiting
Research Site	Rochester	Minnesota	55902	Active, not recruiting
Research Site	Olive Branch	Mississippi	38654	Recruiting
Research Site	Kansas City	Missouri	64151	Withdrawn
Research Site	New York	New York	10065	Withdrawn
Research Site	Cleveland	Ohio	44195	Active, not recruiting
Research Site	Columbus	Ohio	43210	Active, not recruiting
Research Site	Portland	Oregon	97239	Withdrawn
Research Site	Bethlehem	Pennsylvania	18017	Active, not recruiting
Research Site	Philadelphia	Pennsylvania	19104	Active, not recruiting
Research Site	Columbia	South Carolina	29203	Recruiting
Research Site	Brownsville	Texas	78526	Withdrawn
Research Site	Dallas	Texas	75390	Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07007793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 5, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07007793 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →